Key takeaways:

VG801 is a dual-AAV gene therapy in development for the treatment of Stargardt disease.

The therapy is under investigation in a phase 1/2 clinical trial.

Editor’s note: This is a developing news story. Please check back soon for updates.

The FDA granted regenerative medicine advanced therapy designation to VG801 for the treatment of Stargardt disease, according to a press release from VeonGen Therapeutics.

The FDA granted regenerative medicine advanced therapy designation to VG801 for the treatment of Stargardt disease.

VG801, a dual-AAV gene therapy, is being evaluated in a phase 1/2 clinical trial. It previously received rare pediatric disease and orphan drug designations from the FDA, according to the release.

The FDA grants regenerative medicine advanced therapy

See Full Page